# A Study of DM002 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06751329/  
OnCo record `nct06751329` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DM002 in ovarian cancer, prostate cancer, endometrial cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Xadcera Biopharmaceutical (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of DM002 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06751329 by Xadcera Biopharmaceutical (Suzhou) Co., Ltd., with 280 participants planned, started 2025-02-17 and due to reach its primary completion in 2027-10-08. Interventions recorded: DM002.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06751329
- Phase: 1/2
- Setting: A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors
- Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT06751329: https://clinicaltrials.gov/study/NCT06751329

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct06751329.json